Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection.
Well-known cutaneous side effects of interferon (IFN)-alfa therapy include dry skin, pruritus, hair loss, and psoriasis. Presumably because of its potent immunomodulatory activity, the use of IFN-alfa has also led to the development of autoimmune diseases in susceptible individuals. Vitiligo, an autoimmune cutaneous disease, has been reported to occur during IFN-alfa therapy. We report a 10-year-old girl with chronic hepatitis B infection in whom IFN-alfa treatment induced de novo development of vitiligo and psoriasis. Neither skin condition improved after withdrawal of interferon treatment. Concomitant occurrence of vitiligo and psoriasis due to IFN-alfa has not been reported previously.
Seçkin
Deniz
D
Department of Dermatology, Başkent University Faculty of Medicine, Ankara, Turkey. deseckin@hotmail.com
Durusoy
Ciçek
C
Sahin
Sedef
S
D000998:Antiviral Agents / Q000009:adverse effects*; D002648:Child; D003937:Diagnosis, Differential; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D007866:Leg; D011565:Psoriasis / Q000139:chemically induced / Q000150:complications / Q000175:diagnosis* / Q000473:pathology; D011994:Recombinant Proteins; D014820:Vitiligo / Q000139:chemically induced / Q000150:complications / Q000175:diagnosis* / Q000473:pathology
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins